Holen Sie sich die Stockscreener-App
15.30
0.65%
-0.10
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TNDM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$15.40
Offen:
$15.68
24-Stunden-Volumen:
2.51M
Relative Volume:
1.07
Marktkapitalisierung:
$1.05B
Einnahmen:
$1.03B
Nettoeinkommen (Verlust:
$-94.55M
KGV:
-10.92
EPS:
-1.4012
Netto-Cashflow:
$-3.64M
1W Leistung:
-3.16%
1M Leistung:
+13.08%
6M Leistung:
-29.82%
1J Leistung:
-25.02%
1-Tages-Spanne:
$15.08
$15.86
1-Wochen-Bereich:
$15.08
$17.20
52-Wochen-Spanne:
$9.98
$29.65
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Firmenname
Tandem Diabetes Care Inc
Sektor
Branche
Telefon
858-366-6900
Adresse
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
15.30 | 1.05B | 1.03B | -94.55M | -3.64M | -1.4012 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-19 | Hochstufung | Truist | Hold → Buy |
| 2026-03-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-23 | Hochstufung | Lake Street | Hold → Buy |
| 2026-02-20 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-01-27 | Fortgesetzt | TD Cowen | Buy |
| 2025-12-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-21 | Fortgesetzt | Stifel | Hold |
| 2025-09-08 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-06-16 | Eingeleitet | Truist | Hold |
| 2025-04-10 | Eingeleitet | Mizuho | Neutral |
| 2025-03-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-10-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Hochstufung | Stifel | Hold → Buy |
| 2023-08-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-08-09 | Herabstufung | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2020-07-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-18 | Bestätigt | Raymond James | Outperform |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-06 | Eingeleitet | Raymond James | Outperform |
| 2020-02-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Eingeleitet | Guggenheim | Buy |
| 2019-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2019-05-17 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-13 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-03-05 | Bestätigt | BofA/Merrill | Neutral |
| 2019-02-27 | Bestätigt | Lake Street | Buy |
| 2018-11-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-09-26 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten
Tandem Diabetes Care Inc (TNDM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tandem Diabetes Care Inc (TNDM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tandem Diabetes Care Inc (TNDM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tandem Diabetes Care Inc (TNDM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tandem Diabetes Care Inc (TNDM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Precision Trading with Tandem Diabetes Care Inc. (TNDM) Risk Zones - Stock Traders Daily
Tandem Diabetes Care Inc (TNDM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tandem Diabetes Care Inc (TNDM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tandem Diabetes (NASDAQ: TNDM) Rule 144 notice to sell 361 shares - Stock Titan
Tandem Diabetes Care Inc (TNDM) Institutional Confidence - TradingKey
Smart Insulin Pens And Pumps Market Growth to Accelerate by 2035 Amid Rising Diabetes Prevalence and Connected Device InnovationNews and Statistics - IndexBox
Tandem Diabetes (TNDM): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
TANDEM DIABETES CARE INC (TNDM) Stock Chart - ChartMill
Tandem Diabetes Care Q1 earnings call highlights - MSN
Tandem insulin pumps cleared in EU for expanded indications - MSN
TNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin Up - Eastern Progress
Tandem Diabetes Care Inc (TNDM) Shares Surge 5.1% -- What GF Sco - GuruFocus
Why Insulet thinks its fully closed loop system will stand apart from rivals - MedTech Dive
BofA Securities Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $25 - Moomoo
TNDM: Momentum builds with pharmacy transition, Mobi Tubeless launch, and international expansion - TradingView
Tandem Diabetes Care Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
3 takeaways from ADA - MedTech Dive
Tandem Diabetes Care Receives CE Mark Expansion for Type 2 Diabetes and Pregnancy Use of AID Systems - HLTH
Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy - BioSpace
How The Investment Story For Tandem Diabetes Care (TNDM) Is Evolving Without New Analyst Targets - Yahoo Finance
Wall Street analysts see a 56.2% upside in Tandem Diabetes Care (TNDM): Can the stock really move this high? - MSN
Technical Reactions to TNDM Trends in Macro Strategies - Stock Traders Daily
Tandem Diabetes (TNDM) Secures CE Mark for Expanded Use of Insul - GuruFocus
Tandem Diabetes’ Insulin Pumps Win EU Nods for T2D, T1D in Pregnancy - Medical Product Outsourcing
Wall Street Analysts See a 56.2% Upside in Tandem Diabetes Care (TNDM): Can the Stock Really Move This High? - Yahoo Finance
Tandem Diabetes receives CE mark for expanded insulin pump uses By Investing.com - Investing.com Nigeria
Tandem Diabetes receives CE mark for expanded insulin pump uses - Investing.com
[Form 4] TANDEM DIABETES CARE INC Insider Trading Activity - Stock Titan
Diabetes tech companies are racing toward ‘fully closed loop’ devices. But automation comes with trade-offs. - MedTech Dive
Reasons to Add Tandem Diabetes Stock to Your Portfolio Right Now - Yahoo Finance
Tandem: Upgrading To Hold On A High-Stakes Pivot Story - Seeking Alpha
Tandem Diabetes Valuation: Is 1.1x Sales a Buy? - Yahoo Finance
Wells Fargo Upgrade Highlights Tandem Diabetes Care Pharmacy And Pump Shift - Yahoo Finance
Tandem Diabetes Care Hits Day High with 11.16% Surge in Stock Price - Markets Mojo
Tandem Diabetes Care (TNDM) CEO receives 191,103 RSUs under 2023 incentive plan - Stock Titan
Tandem Diabetes Care (TNDM) EVP awarded 29,136 RSUs under 2023 incentive plan - Stock Titan
Tandem Diabetes (TNDM) CFO receives 62,657 restricted stock unit award - Stock Titan
29,136 RSUs granted to Tandem Diabetes Care (TNDM) chief operating officer - Stock Titan
Tandem Diabetes Care (TNDM) EVP receives 29,136 RSU equity award - Stock Titan
Tandem Diabetes Care (TNDM) CTO awarded 26,003 RSUs under 2023 incentive plan - Stock Titan
Tandem Diabetes Care (TNDM) awards 29,136 RSUs to EVP & Chief Legal Officer - Stock Titan
TNDM Stock: What to Know About Tandem's 2026 Reset - TradingView
Why Is Tandem Diabetes (TNDM) Stock Soaring Today - Yahoo Finance
Why is Tandem Diabetes Care stock surging today? By Investing.com - Investing.com Canada
TNDM Upgraded by Wells Fargo -- Price Target Raised to $27 - GuruFocus
Tandem Diabetes (TNDM) Receives Upgrade from Wells Fargo - GuruFocus
Finanzdaten der Tandem Diabetes Care Inc-Aktie (TNDM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):